Quality & origin

New EU regulation on red yeast rice

Archive: Regulation (EU) 2022/860 changed the requirements for monacolins from red yeast rice in June 2022. This article explains the historical product change.
New EU regulation on red yeast rice

Dear customers,

Regulation (EU) 2022/860 entered into force on 21 June 2022. It also affected our products sold at the time as Roter Reis and Roter Reis 5 mg.

The regulation limited total monacolins from red yeast rice to less than 3 mg per portion of the product recommended for daily consumption. The limit does not apply only to monacolin K. It also required warnings, including for pregnant or breastfeeding women, people under 18 or over 70, and people taking cholesterol-lowering medicines or other red yeast rice products.

Another important point for you

The previously authorised health claim for monacolin K required a daily intake of 10 mg. That amount was no longer compatible with the limit introduced in 2022. The claim was formally removed from the EU list by Regulation (EU) 2024/2041. The previous statement that the EFSA had already deleted the claim from its positive list on 21 June 2022 was therefore inaccurate. The European Commission authorises and amends the EU list; the EFSA itself does not.

Following the change, the former Roter Reis 10 mg and Roter Reis 5 mg products were no longer offered at those strengths. The original invitation to stock up before the change has expired and has been removed.

Sources for the editorial corrections

The BioProphyl magazine

Keep exploring

More perspectives from the BioProphyl magazine.

Explore all magazine articles